Redx Pharma Plc

Receive alerts
Market Cap:
£11.42 m
52 weeks high
52 weeks low

Viewing results 1-25 of 51


Redx Pharma told it can up dose in clinical trial of lead cancer drug

RXC004 is what’s known as a Porcupine inhibitor which targets the Wnt signalling pathway – known to be heavily involved in cell growth and division...

4 days, 9 hours ago

Redx Pharma secures short-term funding; assessing longer-term solutions

A loan of up to £2.5mln is being provided by 18.6% shareholder Moulton Goodies...

on 10/6/19

Redx Pharma: Developing treatments for cancer and fibrosis

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors...

on 25/5/19

Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

First-in-man studies of the ROCK2 technology will take place next year...

on 12/2/19

Redx Pharma gets near £870,000 boost to working capital after repayment of loan previously written-off

Following the sale of significant assets by Redag Crop Protection Ltd, the repayment criteria for a loan previously granted to Redag by Redx in October 2014 has been met...

on 6/2/19

Redx Pharma exploring options with interested parties for its NBTI programme after Deinove declines to exercise option

The AIM-listed group said the decision by Deinove follows a period of nine months of evaluation during which it had sole rights to develop the Novel Bacterial Topoisomerase Inhibitor programme...

on 31/1/19

Redx receives regulatory green light to restart research

It means the company is on track to restart the phase I/II study of its next-generation cancer treatment as planned in the first-half ...

on 21/1/19

Redx Pharma looks for some Porcupine help in its fight against cancer and fibrosis

It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive...

on 30/11/18

First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

The data showed RXC006 was able to suppress the Wnt pathway, which is widely believed to be heavily involved in the scarring process associated with lung fibrosis...

on 30/11/18

Redx Pharma appoints CFO as it publishes annual results

Dr James Mead joins the life sciences company on February 1 ...

on 19/11/18

Redx Pharma hails new fibrosis drug candidate

RXC006 is a new breed of pill called a porcupine inhibitor ...

on 14/11/18

Redx Pharma poster assesses the direct tumour targeting of cancer candidate

New data will be unveiled later Monday at a cancer conference in Glasgow...

on 5/11/18

Redx Pharma chief elected to industry body role

From the start of 2019, Lisa Anson will serve as a director of the UK BioIndustry Association for a three-year term...

on 29/10/18

Redx Pharma poster hails the potential of new class of kidney and liver drug

Highly selective ROCK2 inhibitors are thought to suppress the release of pro-fibrotic factors from kidney mesangial cells...

on 26/10/18

Redx Pharma to focus on progressing oncology and fibrotic drugs in 2019

2019 will be an important year for the firm with the re-start of Phase I/IIa trial for RXC004, part of a niche, and potentially breakthrough group of cancer drugs...

on 2/10/18